These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 21664218)
41. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Garmory HS; Griffin KF; Brown KA; Titball RW Vaccine; 2003 Jun; 21(21-22):3051-7. PubMed ID: 12798649 [TBL] [Abstract][Full Text] [Related]
42. Immunogenicity and efficacy of an anthrax/plague DNA fusion vaccine in a mouse model. Albrecht MT; Eyles JE; Baillie LW; Keane-Myers AM FEMS Immunol Med Microbiol; 2012 Aug; 65(3):505-9. PubMed ID: 22515653 [TBL] [Abstract][Full Text] [Related]
43. Prevention of pneumonic plague in mice, rats, guinea pigs and non-human primates with clinical grade rV10, rV10-2 or F1-V vaccines. Quenee LE; Ciletti NA; Elli D; Hermanas TM; Schneewind O Vaccine; 2011 Sep; 29(38):6572-83. PubMed ID: 21763383 [TBL] [Abstract][Full Text] [Related]
44. Yersinia pestis caf1 variants and the limits of plague vaccine protection. Quenee LE; Cornelius CA; Ciletti NA; Elli D; Schneewind O Infect Immun; 2008 May; 76(5):2025-36. PubMed ID: 18347051 [TBL] [Abstract][Full Text] [Related]
46. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Yamanaka H; Hoyt T; Yang X; Golden S; Bosio CM; Crist K; Becker T; Maddaloni M; Pascual DW Infect Immun; 2008 Oct; 76(10):4564-73. PubMed ID: 18694965 [TBL] [Abstract][Full Text] [Related]
47. A vaccinia virus renaissance: new vaccine and immunotherapeutic uses after smallpox eradication. Verardi PH; Titong A; Hagen CJ Hum Vaccin Immunother; 2012 Jul; 8(7):961-70. PubMed ID: 22777090 [TBL] [Abstract][Full Text] [Related]
48. Complete Protection Against Zhang W; Song X; Zhai L; Guo J; Zheng X; Zhang L; Lv M; Hu L; Zhou D; Xiong X; Yang W Front Immunol; 2022; 13():793382. PubMed ID: 35154110 [TBL] [Abstract][Full Text] [Related]
49. Induction of Protective Antiplague Immune Responses by Self-Adjuvanting Bionanoparticles Derived from Engineered Yersinia pestis. Wang X; Singh AK; Zhang X; Sun W Infect Immun; 2020 Apr; 88(5):. PubMed ID: 32152195 [TBL] [Abstract][Full Text] [Related]
50. A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague. Tao P; Mahalingam M; Zhu J; Moayeri M; Sha J; Lawrence WS; Leppla SH; Chopra AK; Rao VB mBio; 2018 Oct; 9(5):. PubMed ID: 30327445 [No Abstract] [Full Text] [Related]
51. Capturing the natural diversity of the human antibody response against vaccinia virus. Lantto J; Haahr Hansen M; Rasmussen SK; Steinaa L; Poulsen TR; Duggan J; Dennis M; Naylor I; Easterbrook L; Bregenholt S; Haurum J; Jensen A J Virol; 2011 Feb; 85(4):1820-33. PubMed ID: 21147924 [TBL] [Abstract][Full Text] [Related]
52. Protecting against plague: towards a next-generation vaccine. Williamson ED; Oyston PC Clin Exp Immunol; 2013 Apr; 172(1):1-8. PubMed ID: 23480179 [TBL] [Abstract][Full Text] [Related]
53. Dual-function antibodies to Yersinia pestis LcrV required for pulmonary clearance of plague. Eisele NA; Anderson DM Clin Vaccine Immunol; 2009 Dec; 16(12):1720-7. PubMed ID: 19828767 [TBL] [Abstract][Full Text] [Related]
54. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols. Thomas RJ; Webber D; Collinge A; Stagg AJ; Bailey SC; Nunez A; Gates A; Jayasekera PN; Taylor RR; Eley S; Titball RW Infect Immun; 2009 Apr; 77(4):1315-23. PubMed ID: 19188359 [TBL] [Abstract][Full Text] [Related]
55. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid. Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652 [TBL] [Abstract][Full Text] [Related]
56. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge. Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079 [TBL] [Abstract][Full Text] [Related]
57. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein. Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354 [TBL] [Abstract][Full Text] [Related]
58. A parenteral DNA vaccine protects against pneumonic plague. Yamanaka H; Hoyt T; Yang X; Bowen R; Golden S; Crist K; Becker T; Maddaloni M; Pascual DW Vaccine; 2010 Apr; 28(18):3219-30. PubMed ID: 20197132 [TBL] [Abstract][Full Text] [Related]